CARDIOVASCULAR AND METABOLIC DISEASES (CVMD)

Cardiovascular disease is responsible for 30% of all deaths globally. Acute coronary syndromes, which include heart attack and unstable angina, are responsible for almost half of all deaths worldwide related to cardiovascular disease. Diabetes is a growing disease and an enormous global burden that is currently projected to affect more than 592 million people by the year 2035. Chronic kidney disease is a complex, debilitating condition that affects more than 70 million people worldwide

ALMEC  has a patient-centric approach to disease treatment, so we are tackling multiple risk factors by uniting our cardiovascular (CV), metabolic and chronic kidney disease (CKD) disease areas into one integrated approach – cardiovascular and metabolic disease (CVMD).

This approach means we look at the CVMD patient as a whole, rather than by disease area, because we know that cardiovascular disease (CVD) is a well-known consequence of diabetes and CKD. Each of our focus areas seek to further reduce cardiovascular morbidity and mortality, and organ damage by addressing multiple CV risk factors.

ALMEC  aims to break through conventional thinking by following what the science is telling us, we will:

  • Continue to build our CV and diabetes portfolio to help a broader range of patients
  • Focus on investigating the impact of treatment options on reducing CV events and death in a broad range of high-risk patients, beyond acute coronary syndromes (ACS)
  • Shift the treatment paradigm of Type 2 diabetes to early combination therapy and accelerate achievement of treatment goals
  • Develop new therapies for anaemia in people with CKD.
Our enduring goal is to push the boundaries of science to deliver life-changing medicines to the people who need them, and contribute to improved health for millions more people around the world.

 

Oncology

At ALMEC , we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.
 
Immuno-Oncology (IO )portfolio is anchored by immune therapies that have been designed to overcome the tumour’s efforts to evade the immune system, such as through the targeted inhibition of immune checkpoints, and through the scientifically driven combination of multiple immune system-stimulating agents, including biologics, small molecules, and chemotherapies. The promise of Immuno-Oncology (IO) is based on the knowledge that the immune system is constantly searching for, assessing, and eliminating foreign particles from the body. Our differentiated strategies of combining IO therapies is key in tumour type cells such as lung cancer, head and neck cancer, bladder cancer, cervical cancer, breast cancer etc. where combined checkpoint blockade will address a significant unmet need for patients who may not benefit from monotherapies.

Inflammation and Immunity

Leveraging our strength and expertise in immunology science, we are focused on gaining a better understanding of the common biology and shared molecular pathways among inflammatory and autoimmune diseases, as well as the fundamental drivers and mechanisms of disease. This approach enables us to identify and select drug targets that have the potential to effectively treat not just one, but multiple inflammatory and autoimmune diseases. Through our advancements in this field, we aim to bring value to the broader scientific community, help redefine standards of care and, ultimately, deliver breakthrough medicines that transform the lives of patients worldwide.

Vaccines and Infections

Infectious diseases are the second-leading cause of death worldwide, after heart disease, and are responsible for more deaths annually than cancer.
At ALMEC We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics.
In INDIA, antimicrobial resistance results in 50,000 deaths from hospital-acquired infections each year, while there are 3-5 million severe cases of influenza each year worldwide. RSV disease is the leading cause of hospitalisation in children under one year of age.
Demand for health interventions to address these burdens of disease remains high and, through working with the wider infection community, we aim to translate science into solutions to address challenges faced in these disease areas.

 

Respiratory

There is an old proverb that states, "Life is in the breath. He who half breathes half  lives."
Many breathing problems are chronic or long-term. These common breathing problems include chronic sinusitis, allergies, and asthma. These problems can cause a host of symptoms such as nasal congestion, runny nose, itchy or watery eyes, chest congestion, cough, wheezing, laboured breathing, and shallow breathing.
More than 75 million people have hay fever or other allergies. And about 50 million people have asthma. Oftentimes, asthma and allergies occur together. When they do, they can make life miserable if left untreated.
Millions worldwide have breathing problems because of chronic obstructive pulmonary disease, or COPD, which includes emphysema and chronic bronchitis. Breathing problems may also stem from other serious problems such as lung cancer, tuberculosis, pneumonia, and lung disease . Some lung diseases lead to respiratory failure.
At ALMEC  developments in the understanding of respiratory disease pathways mean that we are entering an era of unprecedented potential to deliver scientific breakthroughs and transform the lives of people with asthma and COPD through cellular activity involved with targeting a specific pathway that helps us understand how targeted therapies work in respiratory diseases.

A global prospective, observational study in obstructive lung disease, our aim is an innovative new study that aims to support future development of personalised healthcare in asthma and COPD that will deliver the right treatment to the right patient at the right time.